Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$1.09 +1.9%	$1.16	$0.66 ▼ $4.20	$125.71M	2.24	1.59 million shs	1.67 million shs
SAVA Cassava Sciences	$2.34 -2.9%	$2.15	$1.15 ▼ $33.98	$113.05M	-2.05	868,147 shs	610,026 shs
TPST Tempest Therapeutics	$10.53 +11.1%	$7.32	$5.33 ▼ $20.67	$46.75M	-1.93	109,511 shs	223,029 shs
ZNTL Zentalis Pharmaceuticals	$1.59 +7.4%	$1.38	$1.01 ▼ $5.44	$114.70M	1.71	597,704 shs	1.48 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	0.00%	+18.30%	-3.54%	-10.66%	-67.94%
SAVA Cassava Sciences	0.00%	+7.34%	+5.88%	+13.04%	-91.79%
TPST Tempest Therapeutics	0.00%	+43.07%	+67.14%	+58.11%	-43.75%
ZNTL Zentalis Pharmaceuticals	0.00%	+10.42%	+12.77%	+27.20%	-49.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FATE Fate Therapeutics	4.0584 of 5 stars	3.1	2.0	4.7	2.4	2.5	0.6
SAVA Cassava Sciences	2.3192 of 5 stars	1.0	1.0	4.7	2.1	0.8	1.3
TPST Tempest Therapeutics	2.2395 of 5 stars	3.3	2.0	0.0	4.1	0.0	0.6
ZNTL Zentalis Pharmaceuticals	1.8681 of 5 stars	3.3	2.0	0.0	2.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FATE Fate Therapeutics	2.13	Hold	$3.58	228.75% Upside
SAVA Cassava Sciences	2.00	Hold	$2.00	-14.53% Downside
TPST Tempest Therapeutics	2.50	Moderate Buy	$30.00	184.90% Upside
ZNTL Zentalis Pharmaceuticals	2.67	Moderate Buy	$8.20	415.72% Upside

Current Analyst Ratings Breakdown

Latest TPST, FATE, SAVA, and ZNTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$4.00 ➝ $2.50
8/7/2025	ZNTL Zentalis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/7/2025	ZNTL Zentalis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $5.00
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FATE Fate Therapeutics	$13.63M	9.22	N/A	N/A	$2.80 per share	0.39
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	$3.03 per share	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	$5.66 per share	N/A
ZNTL Zentalis Pharmaceuticals	$67.43M	1.70	N/A	N/A	$4.73 per share	0.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FATE Fate Therapeutics	-$186.26M	-$1.45	N/A	N/A	N/A	-2,025.05%	-50.95%	-36.76%	N/A
SAVA Cassava Sciences	-$24.34M	-$2.55	N/A	N/A	N/A	N/A	-59.54%	-50.16%	N/A
TPST Tempest Therapeutics	-$41.84M	-$14.59	N/A	N/A	N/A	N/A	-334.76%	-130.63%	N/A
ZNTL Zentalis Pharmaceuticals	-$165.84M	-$2.26	N/A	N/A	N/A	N/A	-51.62%	-40.28%	N/A

Latest TPST, FATE, SAVA, and ZNTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	SAVA Cassava Sciences	N/A	-$0.18	N/A	-$0.92	N/A	N/A
8/12/2025	Q2 2025	FATE Fate Therapeutics	-$0.35	-$0.29	+$0.06	-$0.29	$1.16 million	$1.91 million
8/11/2025	Q2 2025	TPST Tempest Therapeutics	-$3.23	-$2.07	+$1.16	-$2.07	N/A	N/A
8/6/2025	Q2 2025	ZNTL Zentalis Pharmaceuticals	-$0.56	-$0.37	+$0.19	-$0.37	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FATE Fate Therapeutics	N/A	8.04	8.04
SAVA Cassava Sciences	N/A	9.08	9.08
TPST Tempest Therapeutics	N/A	2.12	2.11
ZNTL Zentalis Pharmaceuticals	N/A	7.99	7.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FATE Fate Therapeutics	97.54%
SAVA Cassava Sciences	38.05%
TPST Tempest Therapeutics	22.52%
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
FATE Fate Therapeutics	5.51%
SAVA Cassava Sciences	12.20%
TPST Tempest Therapeutics	4.70%
ZNTL Zentalis Pharmaceuticals	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FATE Fate Therapeutics	550	115.33 million	108.98 million	Optionable
SAVA Cassava Sciences	30	48.31 million	42.41 million	Optionable
TPST Tempest Therapeutics	20	4.44 million	4.23 million	Optionable
ZNTL Zentalis Pharmaceuticals	160	72.14 million	70.76 million	Optionable

TPST, FATE, SAVA, and ZNTL Headlines

Recent News About These Companies

Wedbush Issues Positive Outlook for ZNTL Earnings

August 12, 2025 | americanbankingnews.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Rating Upgraded by Wall Street Zen

August 11, 2025 | americanbankingnews.com

Leerink Partnrs Has Pessimistic View of ZNTL Q3 Earnings

August 11, 2025 | marketbeat.com

Equities Analysts Offer Predictions for ZNTL Q3 Earnings

August 11, 2025 | marketbeat.com

HC Wainwright Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to "Strong-Buy"

August 10, 2025 | marketbeat.com

Wall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Hold

August 10, 2025 | marketbeat.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results

August 9, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Primecap Management Co. CA

August 9, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $8.37 Consensus PT from Analysts

August 9, 2025 | americanbankingnews.com

Zentalis price target lowered to $5 from $6 at Wells Fargo

August 8, 2025 | msn.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Cut to $5.00 by Analysts at Wells Fargo & Company

August 8, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Federated Hermes Inc.

August 7, 2025 | marketbeat.com

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

August 6, 2025 | globenewswire.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Moderate Buy" by Brokerages

August 6, 2025 | marketbeat.com

GSA Capital Partners LLP Boosts Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

August 3, 2025 | marketbeat.com

Zentalis Pharmaceuticals (ZNTL) Projected to Post Quarterly Earnings on Friday

August 1, 2025 | marketbeat.com

Decheng Capital LLC Lowers Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

July 30, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is favoured by institutional owners who hold 59% of the company

July 24, 2025 | finance.yahoo.com

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

Here's Why We're Watching Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation

June 26, 2025 | finance.yahoo.com

Zentalis Pharmaceuticals shareholders elect three directors at annual meeting

June 20, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST, FATE, SAVA, and ZNTL Company Descriptions

Fate Therapeutics NASDAQ:FATE

$1.09 +0.02 (+1.87%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.12 +0.03 (+3.21%)

As of 08/15/2025 07:59 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Cassava Sciences NASDAQ:SAVA

$2.34 -0.07 (-2.90%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.37 +0.03 (+1.07%)

As of 08/15/2025 07:46 PM Eastern

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Tempest Therapeutics NASDAQ:TPST

$10.53 +1.05 (+11.08%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$10.62 +0.10 (+0.90%)

As of 08/15/2025 07:59 PM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$1.59 +0.11 (+7.43%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.58 -0.01 (-0.31%)

As of 08/15/2025 07:25 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time